Pharmaxis Commences Final Cohort Dosing in Bone Marrow Cancer Phase 1c Trial

4th Aug 21

Release Date: 04/08/2021 8:53am

  • Second Dose Level in PXS-5505 Myelofibrosis Study Showing Dose Related Increase in Blood Drug Levels and Good Safety Profile in Patients
  • Safety Committee Clear Progression to Final Dose

Read full media release - pdf

Categories: News and Media